Iron and colorectal cancer: Evidence from in vitro and animal studies

Nutrition Reviews

Volumn 73, Issue 5, 2015, Pages 308-317

  Padmanabhan, Hari ^a   Brookes, Matthew J ^a   Iqbal, Tariq ^b  

^a ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Colorectal cancer; Heme; Iron; Oxidative stress; Wnt signaling

Indexed keywords

CHELATING AGENT; GLUCOSULFONE; HYDROXYL GROUP; HYDROXYL RADICAL; HYPOXIA INDUCIBLE FACTOR; IRON; LIPID; PROTEIN; TRACE ELEMENT;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; COLON CARCINOGENESIS; COLORECTAL CANCER; DNA DAMAGE; HUMAN; IN VITRO STUDY; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; IRON METABOLISM; NONHUMAN; OXIDATIVE STRESS; STEM CELL; TISSUES; ANIMAL; COLORECTAL NEOPLASMS; DEFICIENCY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ANIMALS; COLORECTAL NEOPLASMS; HUMANS; IRON; OXIDATIVE STRESS; TRACE ELEMENTS;

EID: 84954244079     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1093/nutrit/nuu015     Document Type: Article

References (96)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-E386.
2. Bingham S, Riboli E. Diet and cancer-the European Prospective Investigation into Cancer and Nutrition. Nat Rev Cancer. 2004;4:206-215.
3. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22:191-197.
4. Cummings JH, Bingham SA. Diet and the prevention of cancer. BMJ. 1998;317: 1636-1640.
5. Parkin DM. Studies of cancer in migrant populations: methods and interpretation. Rev Epidemiol Sante Publique. 1992;40:410-424.
6. Gay LJ, Mitrou PN, Keen J, et al. Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk study. J Pathol. 2012;228:405-415.
7. Nelson RL, Davis FG, Sutter E, et al. Body iron stores and risk of colonic neoplasia. J Natl Cancer Institute. 1994;86:455-460.
8. Xue X, Shah YM. Intestinal iron homeostasis and colon tumorigenesis. Nutrients. 2013;5:2333-2351.
9. Chua AC, Klopcic B, Lawrance IC, et al. Iron: an emerging factor in colorectal carcinogenesis. World J Gastroenterol. 2010;16:663-672.
10. Senesse P, Meance S, Cottet V, et al. High dietary iron and copper and risk of colorectal cancer: a case-control study in Burgundy, France. Nutr Cancer. 2004;49: 66-71.
11. Wurzelmann JI, Silver A, Schreinemachers DM, et al. Iron intake and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 1996;5:503-507.
12. Nelson RL. Dietary iron and colorectal cancer risk. Free Radical Biol Med. 1992;12: 161-168.
13. Nelson RL. Iron and colorectal cancer risk: human studies. Nutr Rev. 2001;59: 140-148.
14. Oates PS, West AR. Heme in intestinal epithelial cell turnover, differentiation, detoxification, inflammation, carcinogenesis, absorption and motility. World J Gastroenterol. 2006;12:4281-4295.
15. Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142:24-38.
16. Donovan A, Brownlie A, Zhou Y, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000;403:776-781.
17. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306: 2090-2093.
18. Lund EK, Wharf SG, Fairweather-Tait SJ, et al. Increases in the concentrations of available iron in response to dietary iron supplementation are associated with changes in crypt cell proliferation in rat large intestine. J Nutr. 1998;128:175-179.
19. Lund EK, Wharf SG, Fairweather-Tait SJ, et al. Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers. Am J Clin Nutr. 1999;69:250-255.
20. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol. 2005;202:199-211.
21. Kundu JK, Surh YJ. Emerging avenues linking inflammation and cancer. Free Radical Biol Med. 2012;52:2013-2037.
22. Bubici C, Papa S, Dean K, et al. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene. 2006;25:6731-6748.
23. Davies KJ. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life. 2000;50:279-289.
24. Mates JM, Segura JA, Alonso FJ, et al. Oxidative stress in apoptosis and cancer: an update. Arch Toxicol. 2012;86:1649-1665.
25. Ilsley JN, Belinsky GS, Guda K, et al. Dietary iron promotes azoxymethane-induced colon tumors in mice. Nutr Cancer. 2004;49:162-169.
26. Seril DN, Liao J, Yang CS, et al. Systemic iron supplementation replenishes iron stores without enhancing colon carcinogenesis in murine models of ulcerative colitis: comparison with iron-enriched diet. Dig Dis Sci. 2005;50:696-707.
27. Radulescu S, Brookes MJ, Salgueiro P, et al. Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Reports. 2012;2:270-282.
28. Weinberg ED. Roles of iron in neoplasia. Promotion, prevention, and therapy. Biol Trace Elem Res. 1992;34:123-140.
29. Gatter KC, Brown G, Trowbridge IS, et al. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol. 1983;36: 539-545.
30. Daniels TR, Delgado T, Helguera G, et al. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006;121: 159-176.
31. Okazaki F, Matsunaga N, Okazaki H, et al. Circadian rhythm of transferrin receptor 1 gene expression controlled by c-Myc in colon cancer-bearing mice. Cancer Res. 2010;70:6238-6246.
32. Ohgami RS, Campagna DR, Greer EL, et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nature Genet. 2005;37:1264-1269.
33. Gomes IM, Maia CJ, Santos CR. STEAP proteins: from structure to applications in cancer therapy. Mol Cancer Res. 2012;10:573-587.
34. Zhou XD, DeTolla L, Custer RP, London WT. Iron, ferritin, hepatitis B surface and core antigens in the livers of Chinese patients with hepatocellular carcinoma. Cancer. 1987;59:1430-1437.
35. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Ann N York Acad Sci. 2004;1012:1-13.
36. Evstatiev R, Gasche C. Iron sensing and signalling. Gut. 2012;61:933-952.
37. Wu KJ, Polack A, Dalla-Favera R. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science. 1999;283:676-679.
38. Brookes MJ, Hughes S, Turner FE, et al. Modulation of iron transport proteins in human colorectal carcinogenesis. Gut. 2006;55:1449-1460.
39. Bilello JP, Cable EE, Isom HC. Expression of E-cadherin and other paracellular junction genes is decreased in iron-loaded hepatocytes. Am J Pathol. 2003;162: 1323-1338.
40. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447-5454.
41. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem. 1993;268:21513-21518.
42. Mole DR, Blancher C, Copley RR, et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem. 2009;284:16767-16775.
43. Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002;295:858-861.
44. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004;5:343-354.
45. Kaelin WG. Proline hydroxylation and gene expression. Ann Rev Biochem. 2005; 74:115-128.
46. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437-443.
47. Greer SN, Metcalf JL, Wang Y, et al. The updated biology of hypoxia-inducible factor. EMBO J. 2012;31:2448-2460.
48. Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest. 2013;123: 2337-2343.
49. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A. 2001;98:8780-8785.
50. Liu Q, Davidoff O, Niss K, et al. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest. 2012;122:4635-4644.
51. Lakhal S, Talbot NP, Crosby A, et al. Regulation of growth differentiation factor 15 expression by intracellular iron. Blood. 2009;113:1555-1563.
52. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007; 13:1096-1101.
53. Shimomura M, Hinoi T, Kuroda S, et al. Overexpression of hypoxia inducible factor- 1 alpha is an independent risk factor for recurrence after curative resection of colorectal liver metastases. Ann Surg Oncol. 2013;20 (Suppl 3):S527-S536.
54. Taylor M, Qu A, Anderson ER, et al. Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology. 2011;140:2044-2055.
55. Mastrogiannaki M, Matak P, Delga S, et al. Deletion of HIF-2alpha in the enterocytes decreases the severity of tissue iron loading in hepcidin knockout mice. Blood. 2012;119:587-590.
56. Shah YM, Ito S, Morimura K, et al. Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology. 2008;134:2036-2048.
57. Xue X, Taylor M, Anderson E, et al. Hypoxia-inducible factor-2alpha activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res. 2012;72:2285-2293.
58. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90:5002-5012.
59. Bourseau-Guilmain E, Griveau A, Benoit JP, et al. The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PloS ONE. 2011;6:e25515.
60. Bhanot P, Brink M, Samos CH, et al. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature. 1996;382:225-230.
61. Price MA. CKI, there's more than one: casein kinase I family members in Wnt and Hedgehog signaling. Genes Dev. 2006;20:399-410.
62. Aberle H, Bauer A, Stappert J, et al. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 1997;16:3797-3804.
63. Bienz M. The subcellular destinations of APC proteins. Nat Rev Mol Cell Biol. 2002; 3:328-338.
64. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999;96:5522-5527.
65. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509-1512.
66. Brookes MJ, Boult J, Roberts K, et al. A role for iron in Wnt signalling. Oncogene. 2008;27:966-975.
67. Kolberg M, Strand KR, Graff P, et al. Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta. 2004;1699:1-34.
68. Elford HL, Freese M, Passamani E, et al. Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J Biol Chem. 1970;245:5228-5233.
69. Kwok JC, Richardson DR. The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol/Hematol. 2002;42:65-78.
70. Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood. 2004;104:2967-2975.
71. Liang SX, Richardson DR. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis. 2003;24:1601-1614.
72. Oft M, Heider KH, Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol. 1998;8:1243-1252.
73. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta. 2007;1775:21-62.
74. Chen Z, Zhang D, Yue F, et al. The iron chelators Dp44mT and DFO inhibit TGFbeta- induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem. 2012;287:17016-17028.
75. Saletta F, Suryo Rahmanto Y, Siafakas AR, et al. Cellular iron depletion and the mechanisms involved in the iron-dependent regulation of the growth arrest and DNA damage family of genes. J Biol Chem. 2011;286:35396-35406.
76. Fu D, Richardson DR. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood. 2007;110:752-761.
77. Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood. 2004;104:1450-1458.
78. Roh H, Green DW, Boswell CB, et al. Suppression of beta-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res. 2001;61:6563-6568.
79. Song S, Christova T, Perusini S, et al. Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers. Cancer Res. 2011;71: 7628-7639.
80. Coombs GS, Schmitt AA, Canning CA, et al. Modulation of Wnt/beta-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene. 2012;31: 213-225.
81. Schlemmer U, Frolich W, Prieto RM, et al. Phytate in foods and significance for humans: food sources, intake, processing, bioavailability, protective role and analysis. Mol Nutr Food Res. 2009;53 (Suppl 2):S330-S375.
82. Bozsik A, Kokeny S, Olah E. Molecular mechanisms for the antitumor activity of inositol hexakisphosphate (IP6). Cancer Genomics Proteomics. 2007;4: 43-51.
83. Kapral M, Wawszczyk J, Jurzak M, et al. The effect of inositol hexa phosphate on the expression of selected metalloproteinases and their tissue inhibitors in IL-1beta-stimulated colon cancer cells. Int J Colorectal Dis. 2012;27: 1419-1428.
84. Kapral M, Wawszczyk J, Hollek A, et al. Induction of the expression of genes encoding TGF-beta isoforms and their receptors by inositol hexaphosphate in human colon cancer cells. Acta Pol Pharm. 2013;70:357-363.
85. Parfiniewicz B, Pendzich J, Kapral M, et al. The influence of TNF-alpha on concentration of soluble adhesion molecules in cultures of HT-29 cells exposed to inositol hexaphosphate. Acta Pol Pharm. 2012;69:1291-1297.
86. Reddy BS. Prevention of colon carcinogenesis by components of dietary fiber. Anticancer Res. 1999;19:3681-3683.
87. Norazalina S, Norhaizan ME, Hairuszah I, et al. Anticarcinogenic efficacy of phytic acid extracted from rice bran on azoxymethane-induced colon carcinogenesis in rats. Exp Toxicol Pathol. 2010;62:259-268.
88. Shamsuddin AM, Ullah A. Inositol hexaphosphate inhibits large intestinal cancer in F344 rats 5 months after induction by azoxymethane. Carcinogenesis. 1989;10: 625-626.
89. Shafie NH, Mohd Esa N, Ithnin H, et al. Preventive inositol hexaphosphate extracted from rice bran inhibits colorectal cancer through involvement of Wnt/ beta-catenin and COX-2 pathways. BioMed Res Int. 2013; doi 10.1155/2013/ 681027.
90. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 2002;12:22-29.
91. Zhang Z, Song Y, Wang XL. Inositol hexaphosphate-induced enhancement of natural killer cell activity correlates with suppression of colon carcinogenesis in rats. World J Gastroenterol. 2005;11:5044-5046.
92. Chauhan DP. Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des. 2002;8:1695-1706.
93. Sinha R, Anderson DE, McDonald SS, et al. Cancer risk and diet in India. J Postgrad Med. 2003;49:222-228.
94. Shehzad A, Lee J, Huh TL, et al. Curcumin induces apoptosis in human colorectal carcinoma (HCT-15) cells by regulating expression of Prp4 and p53. Mol Cells. 2013;35:526-532.
95. Carroll RE, Benya RV, Turgeon DK, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res. 2011;4:354-364.
96. Clares B, Biedma-Ortiz RA, Saez-Fernandez E, et al. Nano-engineering of 5-fluorouracil-loaded magnetoliposomes for combined hyperthermia and chemotherapy against colon cancer. EurJ Pharm Biopharm. 2013;85(3 Pt A): 329-338.